european-commission-to-fine-firms-that-have-been-part-of-pay-for-delay-deals-where-brand-name-drug-firms-pay-generic-manufacturers-for-not-delivering-cheaper-versions-of-their-drugs-to-the-market

Ranbaxy, Lundbeck face EU fury for blocking generics

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The European Commission (EC) is going to fine seven generic drug firms, including India-based Ranbaxy and Denmark-based Lundbeck, for limiting the supply... Read more

ema-chmp-gives-thumbs-up-to-pomalidomide-celgene-pomalidomide-for-treatment-of-multiple-myeloma-in-combination-with-dexamethasone

Pomalidomide Celgene gets EU nod for multiple myeloma

  • Europe
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Pomalidomide Celgene (pomalidomide)... Read more

eu-cmdh-endorses-ema-pharmacovigilance-risk-assessment-committee-recommendation-to-stop-marketing-of-oral-medicines-containing-almitrine

EU all set to halt marketing of oral almitrine

  • Europe
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Co-ordination group for Mutual Recognition and Decentralized Procedures - Human (CMDh), a medicines regulatory body representing the European Union (EU),... Read more

glaxosmithkline-s-acquisition-of-okairos-will-help-in-utilize-the-latters-novel-vaccine-platform-technology-in-its-development-of-new-prophylactic-vaccines

GlaxoSmithKline acquires Okairos for $325 mn cash

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: GlaxoSmithKline (GSK) has acquired Okairos, a specialist developer of vaccine platform technologies for $325 million in cash. Swiss-based Okairos has... Read more

glucosamine-supplements-increase-intra-ocular-pressure-thus-leading-to-glaucoma

Body building supplement may lead to eye damage

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Research conducted by scientists at the College of Osteopathic Medicine, University of New England in Biddeford, UK, has highlighted that glucosamine... Read more

major-pharma-firms-conducted-shady-drug-trials-on-east-german-patients-during-1989-90-before-the-fall-of-the-berlin-wall-image-source-www

Big pharma did trials on infants in East Germany in 1989...

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 2 Comments

Singapore: Major pharmaceutical companies, including some that are now subsidiaries of giants Pfizer, Bayer and Roche, conducted several shady drug trials in East... Read more

agilent-france-s-university-of-rouen-and-singapore-s-astar-sign-mou-to-effectively-analyze-biologics-and-vaccines

Agilent, A*Star, French univ sign biologics MoU

  • Singapore
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Agilent Technologies, Glyco-MEV laboratory at the University of Rouen, France, and Bioprocessing Technology Institute (BTI) at the Agency for Science,... Read more

johnson-johnson-launched-11-new-products-since-2009-which-have-raked-in-17-percent-of-its-total-pharma-sales-last-year

J&J to seek nod for 11 new drugs by 2017

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Johnson & Johnson (J&J) revealed that it is aiming to apply for approval of 10 new drugs in the US and Europe, a polio vaccine for other parts of the... Read more

axway-will-help-sanofi-ensure-that-all-divisions-subsidiaries-and-new-acquisitions-are-able-to-efficiently-and-securely-exchange-and-manage-data-in-a-way-that-is-uniform-globally

Axway helps Sanofi to ‘fool-proof’ its IT infrastructure...

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Sanofi joined hands with Axway in order to streamline processes and transform its technology infrastructure into an efficient global network. Axway will... Read more

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X